Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec 28;20(48):18121-30.
doi: 10.3748/wjg.v20.i48.18121.

Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes

Affiliations
Review

Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes

Giovanni Tomasello et al. World J Gastroenterol. .

Abstract

Patients with inflammatory bowel disease (IBD) have an increased risk of 10%-15% developing colorectal cancer (CRC) that is a common disease of high economic costs in developed countries. The CRC has been increasing in recent years and its mortality rates are very high. Multiple biological and biochemical factors are responsible for the onset and progression of this pathology. Moreover, it appears absolutely necessary to investigate the environmental factors favoring the onset of CRC and the promotion of colonic health. The gut microflora, or microbiota, has an extensive diversity both quantitatively and qualitatively. In utero, the intestine of the mammalian fetus is sterile. At birth, the intestinal microbiota is acquired by ingesting maternal anal or vaginal organisms, ultimately developing into a stable community, with marked variations in microbial composition between individuals. The development of IBD is often associated with qualitative and quantitative disorders of the intestinal microbial flora (dysbiosis). The healthy human gut harbours about 10 different bacterial species distributed in colony forming units which colonize the gastrointestinal tract. The intestinal microbiota plays a fundamental role in health and in the progression of diseases such as IBD and CRC. In healthy subjects, the main control of intestinal bacterial colonization occurs through gastric acidity but other factors such as endoluminal temperature, competition between different bacterial strains, peristalsis and drugs can influence the intestinal microenvironment. The microbiota exerts diverse physiological functions to include: growth inhibition of pathogenic microorganisms, synthesis of compounds useful for the trophism of colonic mucosa, regulation of intestinal lymphoid tissue and synthesis of amino acids. Furthermore, mucus seems to play an important role in protecting the intestinal mucosa and maintaining its integrity. Changes in the microbiota composition are mainly influenced by diet and age, as well as genetic factors. Increasing evidence indicates that dysbiosis favors the production of genotoxins and metabolites associated with carcinogenesis and induces dysregulation of the immune response which promotes and sustains inflammation in IBD leading to carcinogenesis. A disequilibrium in gut microflora composition leads to the specific activation of gut associated lymphoid tissue. The associated chronic inflammatory process associated increases the risk of developing CRC. Ulcerative colitis and Crohn's disease are the two major IBDs characterized by an early onset and extraintestinal manifestations, such as rheumatoid arthritis. The pathogenesis of both diseases is complex and not yet fully known. However, it is widely accepted that an inappropriate immune response to microbial flora can play a pivotal role in IBD pathogenesis.

Keywords: Colorectal Cancer; Dismicrobism; Dysbiosis; Eubiosis; Heat shock proteins; Inflammatory bowel disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
One hypothesis on the initiation of the inflammatory process in inflammatory bowel disease bases on an abnormal Th1 response mediated by the secretion of interferon gamma and tumor necrosis factor-α while the chronic inflammation is supported by interleukin-5 and interleukin-13 secreted by Th2 cells. IFN: Interferon; TNF: Tumor necrosis factor; IL: Interleukin; IBD: Inflammatory bowel disease.
Figure 2
Figure 2
Eubiosis and dysbiosis exert different biochemical effects in the context of colocytes pathophysiology. IBD: Inflammatory bowel disease.
Figure 3
Figure 3
At eubiosis stage, the intestinal epithelium hosts a rich and equilibrated microbiota that promotes the barrier function. Microbial dysbiosis favors the production of genotoxins and metabolites associated with carcinogenesis. Moreover dysbiosis induces dysregulation of immune responses that cause inflammation promotion of carcinogenesis. SCFA: Small-chain fatty acids; E. coli: Escherichia coli.

References

    1. Hajj Hussein IA, Tohme R, Barada K, Mostafa MH, Freund JN, Jurjus RA, Karam W, Jurjus A. Inflammatory bowel disease in rats: bacterial and chemical interaction. World J Gastroenterol. 2008;14:4028–4039. - PMC - PubMed
    1. Margiotta G, Sanfilippo A, Accardo FM, Damiani P, Geraci A, Tomasello G. Chronic Inflammatory Bowel Disease in patients with orthopedic manifestation. Comparison with the data reported in international literauture. Euromediterranean Biomedical J. 2012;7:33–38.
    1. Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault ML, Van Nhieu JT, Delchier JC. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol. 2013;6:215–229. - PMC - PubMed
    1. Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A, Tjalsma H. Towards the human colorectal cancer microbiome. PLoS One. 2011;6:e20447. - PMC - PubMed
    1. Turner ND, Ritchie LE, Bresalier RS, Chapkin RS. The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis. Curr Gastroenterol Rep. 2013;15:346. - PMC - PubMed

Publication types